| Amy Elizabeth Gonzalez, MD | |
|
1905 Beaver Ruin Rd, Norcross, GA 30071-3837 | |
| (615) 778-4066 | |
| (615) 778-9114 |
| Full Name | Amy Elizabeth Gonzalez |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 32 Years |
| Location | 1905 Beaver Ruin Rd, Norcross, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326264904 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083X0100X | Preventive Medicine - Occupational Medicine | 054213 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northside Hospital Forsyth | Cumming, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sugarloaf Medical P.c. | 6305923871 | 3 |
News Archive
Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, announced today at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, FDA approval and commercial launch for a full portfolio of pacing, defibrillation and left ventricular leads.
A new Geisinger study begins to unlock the puzzle of painkiller (opioid) addiction - why some people are more likely to become addicted than others. Geisinger investigators have found that patients with four common risk factors have a significantly higher risk of addiction. In addition, a history of severe drug dependence and drug abuse compounds the risk.
It has been known since the 1930s that when a certain part of monkeys' brains were removed, the animals became fearless. Now similar effects are being seen in humans according to a study in the journal Current Biology. Justin Feinstein, the study's lead author and a clinical neuropsychologist at the University of Iowa said, "There's not very many humans with this sort of brain damage… Luckily for us, we had access to a patient, SM, and we studied her different fear behaviours and we read her personal diaries."
Unlocking the mechanisms that cause neurodegenerative prion diseases may require a genetic key, suggest new findings reported by University of Illinois at Chicago distinguished professor of biological sciences Susan Liebman.
› Verified 3 days ago
| Entity Name | Peachtree Immediate Care Fp, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437194156 PECOS PAC ID: 3274559323 Enrollment ID: O20051019000049 |
News Archive
Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, announced today at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, FDA approval and commercial launch for a full portfolio of pacing, defibrillation and left ventricular leads.
A new Geisinger study begins to unlock the puzzle of painkiller (opioid) addiction - why some people are more likely to become addicted than others. Geisinger investigators have found that patients with four common risk factors have a significantly higher risk of addiction. In addition, a history of severe drug dependence and drug abuse compounds the risk.
It has been known since the 1930s that when a certain part of monkeys' brains were removed, the animals became fearless. Now similar effects are being seen in humans according to a study in the journal Current Biology. Justin Feinstein, the study's lead author and a clinical neuropsychologist at the University of Iowa said, "There's not very many humans with this sort of brain damage… Luckily for us, we had access to a patient, SM, and we studied her different fear behaviours and we read her personal diaries."
Unlocking the mechanisms that cause neurodegenerative prion diseases may require a genetic key, suggest new findings reported by University of Illinois at Chicago distinguished professor of biological sciences Susan Liebman.
› Verified 3 days ago
| Entity Name | Sugarloaf Medical P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255483111 PECOS PAC ID: 6305923871 Enrollment ID: O20080408000508 |
News Archive
Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, announced today at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, FDA approval and commercial launch for a full portfolio of pacing, defibrillation and left ventricular leads.
A new Geisinger study begins to unlock the puzzle of painkiller (opioid) addiction - why some people are more likely to become addicted than others. Geisinger investigators have found that patients with four common risk factors have a significantly higher risk of addiction. In addition, a history of severe drug dependence and drug abuse compounds the risk.
It has been known since the 1930s that when a certain part of monkeys' brains were removed, the animals became fearless. Now similar effects are being seen in humans according to a study in the journal Current Biology. Justin Feinstein, the study's lead author and a clinical neuropsychologist at the University of Iowa said, "There's not very many humans with this sort of brain damage… Luckily for us, we had access to a patient, SM, and we studied her different fear behaviours and we read her personal diaries."
Unlocking the mechanisms that cause neurodegenerative prion diseases may require a genetic key, suggest new findings reported by University of Illinois at Chicago distinguished professor of biological sciences Susan Liebman.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amy Elizabeth Gonzalez, MD 5080 Spectrum Drive, Suite 1200 West Tower, Addison, TX 75001 Ph: (800) 232-3550 | Amy Elizabeth Gonzalez, MD 1905 Beaver Ruin Rd, Norcross, GA 30071-3837 Ph: (615) 778-4066 |
News Archive
Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, announced today at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, FDA approval and commercial launch for a full portfolio of pacing, defibrillation and left ventricular leads.
A new Geisinger study begins to unlock the puzzle of painkiller (opioid) addiction - why some people are more likely to become addicted than others. Geisinger investigators have found that patients with four common risk factors have a significantly higher risk of addiction. In addition, a history of severe drug dependence and drug abuse compounds the risk.
It has been known since the 1930s that when a certain part of monkeys' brains were removed, the animals became fearless. Now similar effects are being seen in humans according to a study in the journal Current Biology. Justin Feinstein, the study's lead author and a clinical neuropsychologist at the University of Iowa said, "There's not very many humans with this sort of brain damage… Luckily for us, we had access to a patient, SM, and we studied her different fear behaviours and we read her personal diaries."
Unlocking the mechanisms that cause neurodegenerative prion diseases may require a genetic key, suggest new findings reported by University of Illinois at Chicago distinguished professor of biological sciences Susan Liebman.
› Verified 3 days ago
Dr. Louise Farmer Sheffield, MD Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 6825 Jimmy Carter Blvd, Suite1100, Norcross, GA 30071 Phone: 404-855-3300 Fax: 404-855-4331 | |
Jane Turley Stclair, MD,MPH Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 6825 Jimmy Carter Blvd, Suite 1100, Norcross, GA 30071 Phone: 770-449-5161 Fax: 770-449-3272 | |
Jennifer L Andreae, THERAPY DIR. I Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 1905 Beaver Ruin Rd, Norcross, GA 30071 Phone: 615-778-4066 | |
Dr. Patricia Ann Blackwell, MD Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 1905 Beaver Ruin Rd, Norcross, GA 30071 Phone: 770-441-0444 |